Tjon Pian Gi Robin E A, San Giorgi Michel R M, Pawlita Michael, Michel Angelika, van Hemel Bettien M, Schuuring Ed M D, van den Heuvel Edwin R, van der Laan Bernard F A M, Dikkers Frederik G
Department of Otorhinolaryngology/Head and Neck Surgery, University of Groningen, University Medical Center Groningen, P.O. Box 30.001, 9700 RB, Groningen, The Netherlands.
Graduate School of Medical Sciences (Cancer Research Center Groningen), University of Groningen, Groningen, The Netherlands.
Eur Arch Otorhinolaryngol. 2016 Oct;273(10):3231-6. doi: 10.1007/s00405-016-4085-3. Epub 2016 May 17.
Aim of this study was to explore influence of the quadrivalent HPV vaccine (Gardasil(®)) on the immune status of recurrent respiratory papillomatosis (RRP) patients. In retrospective observational study, six RRP patients who received the quadrivalent HPV vaccine and whose HPV seroreactivity was measured were included. Multiplex HPV Serology was used to determine HPV-specific antibodies pre- and post-vaccination. Surgical interventions and patient records were analyzed. Five HPV6 and 1 HPV11 infected patient were included. Mean antibody reactivity against the associated HPV type rose from 1125 median fluorescence intensity (MFI) pre-vaccination to 4690 MFI post-vaccination (p < 0.001). Median post-vaccination follow-up was 4 years. Poisson regression analysis showed that the quadrivalent HPV vaccine decreased the incidence rate of surgeries. The immune system of RRP patients is able to increase antibody reactivity against the associated HPV type. A double blind randomized controlled trial is needed to determine whether this immunological increase can cause decrease in number of surgeries.
本研究的目的是探讨四价人乳头瘤病毒疫苗（佳达修（®））对复发性呼吸道乳头瘤病（RRP）患者免疫状态的影响。在一项回顾性观察研究中，纳入了6例接受四价人乳头瘤病毒疫苗且检测了HPV血清反应性的RRP患者。采用多重HPV血清学方法测定接种疫苗前后的HPV特异性抗体。分析了手术干预措施和患者记录。纳入了5例HPV6感染患者和1例HPV11感染患者。接种疫苗后，针对相关HPV型别的平均抗体反应性从接种前的1125中位荧光强度（MFI）升至接种后的4690 MFI（p < 0.001）。接种疫苗后的中位随访时间为4年。泊松回归分析显示，四价人乳头瘤病毒疫苗降低了手术发生率。RRP患者的免疫系统能够提高针对相关HPV型别的抗体反应性。需要进行一项双盲随机对照试验来确定这种免疫增强是否会导致手术次数减少。
